A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen
The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.
Inclusion Criteria:
1. Target Population
Exclusion Criteria:
Target Disease Exceptions
Medical History and Concurrent Diseases
Prohibited Treatments and/or Restricted Therapies
Fullerton, California 92835, United States
Pemroke Pines, Florida 33028, United States
Indianapolis, Indiana 46202, United States
Greeville, North Carolina 27834, United States